When the relationships with immature markers for secondary AML were evaluated, only correlations between sensitivity to daunorubicin and expression of CD34 in cohort 3 (weak) and cohort 4 (moderate) were found (Table 2). Here, CD34 is linked to acute myeloid leukemia.